Aurinia Pharmaceuticals Inc.
AUPH
$7.81
-$0.24-2.98%
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
--
Headlines
4/5/2025
-
Tickeron - Stocks
4/4/2025
-
Tickeron - Stocks
4/3/2025
-
Tickeron - Stocks
Aurinia Pharmaceuticals (AUPH, $8.05) Stochastic Oscillator left the oversold zone on April 01, 2025
4/2/2025
-
Tickeron - Stocks
4/1/2025
-
Simply Wall St
4/1/2025
-
Tickeron - Stocks
4/1/2025
-
Tickeron - Technical Analysis
4/1/2025
-
Tickeron - Technical Analysis
3/29/2025
-
Tickeron - Stocks
3/29/2025
-
Ticker Report
3/29/2025
-
MarketBeat
3/29/2025
-
MarketBeat
3/28/2025
-
Ticker Report
3/26/2025
-
Tickeron - Technical Analysis
3/22/2025
-
Tickeron - Stocks
3/21/2025
-
Tickeron - Stocks
3/20/2025
-
Zacks Investment Research
3/20/2025
-
Tickeron - Stocks
3/17/2025
-
Ticker Report
3/17/2025
-
MarketBeat
3/14/2025
-
Tickeron - Stocks
3/8/2025
-
MarketBeat
3/8/2025
-
MarketBeat
3/7/2025
-
Stock Options Channel
3/7/2025
-
Ticker Report
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, February 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Beginning of May (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
250-744-2487
Address
#140, 14315 – 118 Avenue
Edmonton, AB T5L 4S6
Edmonton, AB T5L 4S6
Country
Year Founded
Business Description
Sector
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, focuses on delivering therapies to treat autoimmune diseases with unmet medical needs in the United States. It offers LUPKYNIS...
more
